Skip to main content
Lepu Biopharma Co., Ltd. logo

Lepu Biopharma Co., Ltd. — Investor Relations & Filings

Ticker · 2157 ISIN · CNE100004SM4 HKEX Manufacturing
Open in API
Filings indexed 240 across all filing types
Latest filing 2023-05-03 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2157

About Lepu Biopharma Co., Ltd.

http://www.lepubiopharma.com

Lepu Biopharma Co., Ltd. is an innovation-driven biopharmaceutical company dedicated exclusively to the research and development of oncology therapeutics. The company focuses on advanced tumor treatment modalities, including targeted therapy and cancer immunotherapy. Its strategically built product pipeline encompasses a range of candidate drugs, notably Antibody-Drug Conjugates (ADCs), immunotherapies, and oncolytic virus drugs, with assets spanning clinical and preclinical development stages. Lepu Biopharma leverages its proprietary ADC technology platform to drive the development of innovative treatments. The company pursues domestic commercialization through dedicated sales infrastructure while actively seeking global market access, particularly in the US and European markets, via strategic partnerships and out-licensing agreements for its drug candidates.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2023
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 30 April 2023. It details movements in authorised/registered share capital, issued shares, and confirms compliance with listing rules. It is a regulatory submission to the Hong Kong Exchanges and Clearing Limited, focusing on share capital and share movements. There is no financial performance data, earnings, or management discussion. The document is a regulatory filing reporting share capital and share movements as required by listing rules, not a financial report or announcement of voting results. Therefore, it fits best under Regulatory Filings (RNS). The document length (7380 characters) and detailed content confirm it is not a brief announcement but a formal regulatory filing.
2023-05-03 English
CLOSURE OF REGISTER OF MEMBERS FOR ANNUAL GENERAL MEETING TO BE HELD ON JUNE 15, 2023
AGM Information Classification · 95% confidence The document is an announcement regarding the closure of the register of members for the upcoming Annual General Meeting (AGM) of Lepu Biopharma Co., Ltd. It specifies the dates for the register closure and instructions for shareholders to be eligible to attend and vote at the AGM. It also mentions that the circular with details of resolutions and proxy forms will be sent later. The document does not contain any financial data, results, or detailed report content but is clearly related to the AGM event logistics and shareholder eligibility. Therefore, it fits the category of AGM Information (AGM-R). The document length is short and it is an announcement, not the full AGM materials or minutes.
2023-04-26 English
Terms of Reference for Remuneration and Appraisal Committee
Remuneration Information Classification · 95% confidence The document is titled 'REMUNERATION AND APPRAISAL COMMITTEE UNDER THE BOARD OF DIRECTORS TERMS OF REFERENCE' and details the composition, responsibilities, meetings, and procedural rules of the Remuneration and Appraisal Committee under the board of directors of Lepu Biopharma Co., Ltd. It focuses on remuneration policies, appraisal standards, committee member duties, and governance related to executive compensation. There is no financial data, earnings information, or report publication mentioned. The content is about governance structure and committee terms related to remuneration, which fits the definition of Remuneration Information filings. Therefore, the document is best classified as Remuneration Information (DEF 14A).
2023-04-26 English
2022 Annual Report
Annual Report Classification · 100% confidence The document is titled '2022 Annual Report' for Lepu Biopharma Co., Ltd. It contains detailed sections typical of an annual report, including Chairman's Statement, Management Discussion and Analysis, Biographies of Directors, Corporate Governance Report, Environmental, Social and Governance Report, Independent Auditor's Report, and comprehensive financial statements such as Consolidated Statement of Comprehensive Loss, Balance Sheet, and Notes to Financial Statements. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The content covers company performance, strategy, governance, and audited financials for the fiscal year ended December 31, 2022. Therefore, this document fits the definition of an Annual Report (10-K). FY 2022
2023-04-26 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2023
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 31 March 2023. It details movements in authorised/registered share capital, issued shares, and confirms compliance with listing rules. There is no financial performance data, earnings, or management discussion. The document is a regulatory submission about share capital and share movements, typical of a regulatory filing to the Hong Kong Stock Exchange. It is not an annual or interim report, earnings release, or capital raising announcement. It is a compliance report on share capital and securities movements under exchange rules, fitting the Regulatory Filings (RNS) category as a general regulatory announcement that does not fit other specific categories.
2023-04-04 English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2022
Annual Report Classification · 95% confidence The document is titled 'ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2022' and contains detailed audited consolidated annual results, business highlights, management discussion and analysis, product pipeline, and financial highlights for the full fiscal year 2022. It includes comprehensive financial data such as revenue, profit, expenses, and cash equivalents, as well as detailed descriptions of business operations and clinical progress. The length is substantial (15,000 characters), indicating it is a full report rather than a brief announcement or summary. The content aligns with a full Annual Report (10-K equivalent) rather than a short Earnings Release or Regulatory Filing. Therefore, the document should be classified as an Annual Report (10-K). FY 2022
2023-03-17 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.